Preferred Label : zanidatamab;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/ziihera
2026
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
biliary tract neoplasms
infusions, intravenous
adult
zanidatamab
zanidatamab
zanidatamab
antibodies, bispecific
antibodies, bispecific
HER2 positive biliary tract cancer
HER2/Neu Positive

---
https://ansm.sante.fr/tableau-acces-derogatoire/zanidatamab
2025
false
false
false
France
French
infusions, intravenous
zanidatamab
drug information
summary of product characteristics
package leaflet
adult
biliary tract neoplasms
HER2 positive biliary tract cancer
HER2/Neu Expression by Immunohistochemistry 3+
zanidatamab
Locally Advanced Bile Duct Carcinoma
Metastatic Bile Duct Carcinoma
Unresectable Bile Duct Carcinoma
guidelines for drug use

---
https://www.has-sante.fr/jcms/p_3563099/fr/ziihera-zanidatamab-cancer-des-voies-biliaires
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
HER2/Neu Expression by Immunohistochemistry 3+
adult
guidelines for drug use
infusions, intravenous
zanidatamab
evaluation of the transparency committee
biliary tract cancer
zanidatamab
biliary tract neoplasms

---
Nous contacter.
28/01/2026


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.